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Abstract 
Mutations in the lamin A/C gene (LMNA) encoding the nuclear intermediate filament proteins 
lamins A and C cause a group of tissue-selective diseases, the most common of which is dilated 
cardiomyopathy (herein referred to as LMNA cardiomyopathy) with variable skeletal muscle 
involvement.  We previously showed that cardiomyocyte-specific overexpression of dual 
specificity protein phosphatase 4 (DUSP4) is involved in the pathogenesis of LMNA 
cardiomyopathy. However, how mutations in LMNA activate Dusp4 expression and whether it is 
necessary for the development of LMNA cardiomyopathy are currently unknown. We now show 
that female LmnaH222P/H222P mice, a model for LMNA cardiomyopathy, have increased Dusp4 
expression and hyperactivation of extracellular signal-regulated kinase (ERK) 1/2 with delayed 
kinetics relative to male mice, consistent with the sex-dependent delay in the onset and 
progression of disease. Mechanistically, we show that the H222P amino acid substitution in 
lamin A enhances its binding to ERK1/2 and increases sequestration at the nuclear envelope.  
Finally, we show that genetic deletion of Dusp4 has beneficial effects on heart function and 
prolongs survival in LmnaH222P/H222P mice. These results further establish Dusp4 as a key 
contributor to the pathogenesis of LMNA cardiomyopathy and a potential target for drug therapy. 
3 
Introduction 
 Mutations in the LMNA gene, which encodes lamins A and C (lamin A/C), cause a 
diverse group of diseases termed laminopathies. Despite its expression in most differentiated 
mammalian somatic cells, specific mutations in LMNA lead to tissue-selective diseases affecting 
striated muscle, adipose or peripheral nerve as well as multi-system disorders with features of 
accelerated aging, such as Hutchinson-Gilford progeria syndrome (1). The most prevalent 
laminopathy is dilated cardiomyopathy (LMNA cardiomyopathy, OMIM #115200) with variable 
skeletal muscle involvement, which includes autosomal Emery-Dreifuss muscular dystrophy and 
limb-girdle muscular dystrophy type 1B (2-5). LMNA cardiomyopathy, which may account for 
about 8% of familial cardiomyopathies, is characterized by early-onset conduction defects, 
ventricular dilatation, impaired contractility, and cardiac fibrosis, almost always progressing to 
congestive heart failure if not preceded by sudden death from cardiac dysrhythmia (6-11). 
Current therapeutic interventions involve implantable pacemakers and defibrillators as well as 
drugs commonly used to treat the symptoms of congestive heart failure such as angiotensin 
pathway inhibitors, aldosterone antagonists, diuretics, and beta-adrenergic blockers. While these 
therapies can prolong patient survival, they are targeted more at mitigating the complications and 
secondary features of the disease rather than the underlying pathogenic mechanisms. 
 Lamin A/C are intermediate filament proteins that constitute a major component of the 
nuclear lamina, a proteinaceous meshwork lining the inner nuclear membrane of metazoan cells 
(12). Although lamin A/C are widely accepted to provide structural support to the nucleus and 
maintain chromatin structure, more recent evidence demonstrates a dynamic role in regulating 
gene expression. For example, through epigenetic mechanisms, lamin A/C regulate gene 
expression programs necessary for tissue differentiation during development (13, 14). 
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Additionally, lamin A/C have been shown to act as a molecular scaffold that modulates cell 
signaling within the nuclear interior. The proteins directly interact with mitogen-activated protein 
(MAP) kinase extracellular signal-regulated kinase (ERK) 1/2 and its downstream transcription 
factor c-Fos, facilitating c-Fos phosphorylation at the nuclear lamina (15, 16). Consistent with 
the regulatory role of lamin A/C in ERK1/2 signaling, ERK1/2 phosphorylation (which is 
indicative of its activation) is enhanced in hearts of human subjects with LMNA cardiomyopathy 
and in the LmnaH222P/H222P murine model (17, 18). LmnaH222P/H222P mice recapitulate the cardiac 
pathology observed in human subjects, with male mice developing the disease with faster 
kinetics relative to female mice (19). Notably, the reduction of ERK1/2 signaling in these mice 
through genetic or pharmacological means achieves salutary effects on the heart as well as a 
prolongation of survival (18, 20-22). 
 We have previously implicated the Dusp4 gene encoding nuclear-resident dual specificity 
protein phosphatase 4 (DUSP4), which belongs to a superfamily of type I cysteine-based 
phosphatases that target MAP kinases, in the development of LMNA cardiomyopathy (23). We 
showed that Dusp4 is overexpressed specifically in hearts of male LmnaH222P/H222P mice prior to 
detectable signs of cardiomyopathy and its expression is concomitant with activated protein 
kinase B (AKT)-mammalian target of rapamycin complex 1 (mTORC1) signaling and impaired 
autophagy (23, 24). Moreover, transgenic mice with cardiac-specific overexpression of Dusp4 
exhibit molecular changes and heart defects analogous to those observed in the LmnaH222P/H222P 
mice, indicating that Dusp4 overexpression is sufficient for the development of cardiomyopathy 
similar to that caused by Lmna mutations (23). 
 Early studies demonstrated that exposure of cells to fetal calf serum enhanced DUSP4 
expression in an ERK1/2-dependent manner and its overexpression inhibited ERK1/2-dependent 
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gene transcription (25-27). Based on these initial observations, as well as subsequent studies 
showing DUSP4-mediated dephosphorylation of additional members of the MAP kinase 
pathway, the primary function of this phosphatase was hypothesized to establish feedback 
inhibition of MAP kinase signaling (28-30). More recent studies have demonstrated diverse 
cellular inputs in addition to ERK1/2 signaling can stimulate Dusp4 transcription (31-37). 
DUSP4 has also been shown to have other molecular functions besides MAP kinase 
dephosphorylation (38, 39). 
Pharmacological inhibition of ERK1/2 suppresses Dusp4 expression in hearts from 
LmnaH222P/H222P mice and in vitro cell culture models (23). Although this suggests that ERK1/2 
signaling is a predominant driver of DUSP4 expression in the heart in LMNA cardiomyopathy, 
confirmatory studies independent of pharmacological inhibitors are lacking.  It is also unknown 
whether cardiomyopathy-causing Lmna mutations have a more direct effect on transcriptional 
activation as a result of epigenetic dysregulation on the Dusp4 locus. Lastly, it is unknown 
whether DUSP4 protein overexpression, while shown to be sufficient, is required for the full 
phenotypic development of LMNA cardiomyopathy. In this study, we further establish DUSP4 as 
a mediator of LMNA cardiomyopathy pathogenesis by assessing the kinetics of its expression in 
hearts of female LmnaH222P/H222P mice that develop cardiac disease later than male mice. Using 
cellular models expressing disease-causing lamin A variants, we also present data suggestive of 
the molecular mechanisms that may underlie enhanced cardiac Dusp4 expression in 
LmnaH222P/H222P mouse hearts. Lastly, we devise a model in which Dusp4 is deleted from mice on 





Enhanced Dusp4 expression in ventricular tissue of female LmnaH222P/H222P mice correlates 
with increases in markers of heart failure and fibrosis. Female LmnaH222P/H222P mice develop 
dilated cardiomyopathy but with delayed kinetics relative to male mice (19). We previously 
reported enhanced ventricular Dusp4 expression in male LmnaH222P/H222P mice starting as early as 
4 weeks of age (23). We have also noted delayed kinetics of Dusp4 expression in hearts of 
female LmnaH222P/H222P mice relative to males (23) but these initial observations were not fully 
explored. We therefore screened for the expression of 11 Dusp mRNAs in hearts of 20 week-old 
female LmnaH222P/H222P mice using quantitative real-time PCR (qPCR) (Fig. 1A). Similar to 
observations in male mice, we observed a specific statistically significant increase in Dusp4 
mRNA expression (approximately 8-fold) in hearts of 20 week-old female LmnaH222P/H222P mice 
relative to Lmna+/+ counterparts (Fig. 1A). The increased Dusp4 expression was limited to 
cardiac and skeletal muscle (Fig. 1B). It was detectable at 20 weeks of age but not at 10 weeks of 
age, which is 6 weeks later than increased Dusp4 expression is detected in hearts of male 
LmnaH222P/H222P mice (23) (Fig. 1C). To determine whether the increased Dusp4 expression 
accompanied hyperactivated ERK1/2 and AKT signaling, as previously demonstrated in the 
hearts of male LmnaH222P/H222P mice (17, 24), we assessed the expression of activated 
(phosphorylated) forms of these two signaling molecules. Consistent with the kinetics of DUSP4 
expression, we observed increased levels of activated ERK1/2 and AKT, albeit with some animal 
to animal variability, in hearts of female LmnaH222P/H222P mice at 20 and 30 weeks of age but not 
at 10 weeks (Fig. 1D). 
 To determine if Dusp4 expression coincided with expression of markers of heart failure, 
we examined the expression kinetics of natriuretic factors encoded by Nppa and Nppb, which are 
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expressed as a consequence of left ventricular dilatation. Similar to Dusp4 expression, Nppa and 
Nppb mRNA expression in hearts of female LmnaH222P/H222P mice was detected at 20 weeks of 
age and was further increased at 30 weeks (Fig. 2A). The increase in Nppa mRNA expression led 
to an increase in expression of the encoded atrial natriuretic protein (Fig. 2B). In addition, we 
measured mRNA levels of several collagen isoforms to assess for fibrotic responses. The level of 
type I collagen mRNA (Col1a2), which is only expressed by cardiac fibroblasts in the heart (40, 
41), was significantly enhanced by 10 weeks of age, prior to other detectable cardiac 
abnormalities, and further increased at 20 and 30 weeks (Fig. 2C). In contrast, collagen type IV 
mRNA (Col4a1, Col4a2), which is expressed by both cardiac fibroblasts and cardiomyocytes 
(40, 41), showed modest increases that reached statistical significance only at 30 weeks of age 
(Fig. 2C). These data demonstrated that in female LmnaH222P/H222P mice, enhanced cardiac Dusp4 
expression accompanied altered cell signaling and expression of markers of left ventricular 
dilatation. In contrast, male LmnaH222P/H222P have earlier onset of Dusp4 expression and altered 
cell signaling.  
 
Enhanced Dusp4 expression resulting from Lmna mutation is primarily driven by ERK1/2 
pathway. Pharmacological inhibition of ERK1/2 activity suppresses Dusp4 expression in hearts 
of LmnaH222P/H222P mice and in vitro cell culture models (23).  This suggests that ERK1/2 
signaling is the primary driver of increased Dusp4 expression in hearts with a cardiomyopathy-
causing Lmna mutation. However, it is plausible that Lmna mutation directly impinges on Dusp4 
expression independent of ERK1/2 pathway activation. Lamin A/C play a role in epigenetic 
regulation and pathogenic mutations in the Lmna gene cause alterations in epigenetic control (13, 
14, 42). To determine whether the H222P lamin A/C expressed in LmnaH222P/H222P mice directly 
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influence Dusp4 expression by eliciting epigenetic changes at the Dusp4 locus, we assessed its 
methylation and histone acetylation status upstream and downstream of the transcriptional start 
site. 
 To ascertain the likelihood of Dusp4 methylation, we first performed in silico analysis for 
the presence of CpG islands within this locus. We analyzed a continuous stretch 2,000 bp pairs 
encompassing the predicted transcriptional start site (TSS) within the Dusp4 locus and found two 
prominent CpG islands that spanned the previously described promoter/enhancer regions (31, 34-
37) (Fig. S1A). To determine if specific CpG dinucleotides within the islands were methylated, 
we employed a strategy utilizing methylation-sensitive restriction enzyme digest analysis (Fig. 
S1B). We scanned the predicted CpG islands for the presence of both methylation sensitive and 
insensitive restriction endonuclease sites within close proximity to each other and found two 
such sites. The presence of DNA methylation was tested at these two sites in genomic DNA 
isolated from ventricular tissue of 8 week-old male LmnaH222P/H222P mice and compared to 
Lmna+/+ counterparts. We found that both methylation sensitive and insensitive restriction 
enzymes were able to digest the genomic DNA and prevent amplicon generation using both 
semi-quantitative PCR (Fig. S1C-E) and quantitative PCR (Fig. S1F). This indicated that these 
specific sites within two prominent CpG islands within the Dusp4 locus were not methylated. As 
a confirmatory experiment, we also cultured C2C12 cells stably expressing the H222P variant of 
FLAG-tagged lamin A, which overexpress Dusp4 under glucose starvation (23), in the presence 
of the methylation inhibitor 5-aza-2'-deoxycytidine (5-AC). The presence of 5-AC (at 1 PM and 
5 PM for 72 hr) did not further enhance Dusp4 expression under either basal or glucose starved 
conditions (Fig. S2). Hence, our data indicated that enhanced Dusp4 gene expression in hearts of 
LmnaH222P/H222P mice was not mediated by altered promoter/enhancer methylation. 
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 Because DNA methylation did not appear to influence Dusp4 expression, we performed 
chromatin immunoprecipitation (ChIP) analyses to determine if the H222P lamin A/C alter 
histone-3 acetylation (Ac-H3) at the Dusp4 locus. Ac-H3-bound genomic DNA was 
immunoprecipitated from extracts of ventricular tissue of 8 week-old male Lmna+/+ and 
LmnaH222P/H222P mice and probed for the enrichment of sequences that spanned the Dusp4 
transcriptional start site (Fig. 3A). qPCR analyses using two separate primer sets revealed a 
statistically significant increase in Ac-H3 at the Dusp4 locus (Fig. 3B). This enhancement in Ac-
H3 could be a direct result of H222P lamin A/C expression or occur indirectly via the ERK1/2 
pathway, which is activated in hearts of male LmnaH222P/H222P mice by 4 weeks of age (17, 23). 
To address this issue, we performed ChIP assays on C2C12 cells stably expressing either FLAG-
tagged wild type (WT) or H222P lamin A. When subjected to glucose deprivation, these cells 
recapitulate the phospho-ERK1/2 and Dusp4 expression profiles observed in heart tissue of 
Lmna+/+ and LmnaH222P/H222P mice (23). Under basal conditions, we observed no difference in the 
levels of Ac-H3 at the Dusp4 locus between C2C12 cells expressing WT or H222P lamin A; 
however, upon removal of glucose, we observed significant increases in Ac-H3 only in cells 
expressing H222P lamin A (Fig. 3C). Given the inducibility of Ac-H3 at the Dusp4 locus upon 
glucose deprivation, we surmised that this induction is due to the preferential increase in 
phospho-ERK1/2 as previously shown in C2C12 cells expressing H222P lamin A (23). 
Pretreatment of C2C12 cells with PD98059, which blocks ERK1/2 activity by inhibiting the 
upstream activator MEK1/2, abolished Ac-H3 enhancement at the Dusp4 locus induced by 
glucose deprivation (Fig 3D). These data suggested that Ac-H3 at the Dusp4 locus in cells 
expressing H222P lamin A variant, is primarily mediated by ERK1/2 activation. 
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 To reinforce our data indicating that ERK1/2 signaling is the primary driver of Dusp4 
expression without relying on pharmacological inhibitors, we assessed its expression in hearts of 
LmnaH222P/H222P mice that were interbred with Mapk3-/- (encoding ERK1) mice to remove the 
influence of ERK1 (21) (Fig. 4A). Depletion of ERK1 from LmnaH222P/H222P mice prolonged 
survival and improved left ventricular function, which was abrogated at ages greater than 20 
weeks in male mice due to compensatory ERK2 hyperactivation (21). Expression of total and 
phosphorylated ERK1 were absent in hearts of LmnaH222P/H222P/Mapk3-/- mice (Fig. 4B, top 
panel). This lack of ERK1 almost completely abolished Dusp4 mRNA expression in hearts of 
LmnaH222P/H222P/Mapk3-/- mice at both 4 and16 weeks of age relative to LmnaH222P/H222P/Mapk3+/+ 
mice despite the presence of phospho-ERK2 (Fig. 4B, bottom panel). To further confirm that 
Dusp4 mRNA expression was primarily driven by ERK1/2-signaling, we also assessed the 
signaling status of p53, transforming growth factor-E (TGF-E), and the expression of E2F 
Transcription Factor 1, all of which have been shown to activate Dusp4 transcription (32-35). 
We observed no significant changes in phosphorylated p53, phosphorylated Smad3 (induced by 
TGF-E signaling) or E2f1 mRNA encoding E2F Transcription Factor 1 between hearts of 4 
week-old Lmna+/+ and LmnaH222P/H222P mice (Fig. S3). Although TGF-E signaling has been 
shown to be activated in hearts of male LmnaH222P/H222P mice at 20 weeks of age (19, 43), we saw 
no evidence of its activation at 4 weeks, which is the earliest age at which Dusp4 is 
overexpressed (23). These results demonstrated that enhanced ERK1/2 signaling underlies 
Dusp4 overexpression in hearts of LmnaH222P/H222P mice. 
 
H222P lamin A preferentially sequesters ERK1/2 at the nuclear lamina. Previous studies 
have demonstrated that lamin A/C can bind to phospho-ERK1/2 and that the resulting 
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recruitment of these protein kinases to the nuclear lamina may facilitate the downstream 
propagation of mitogenic signaling (15, 16). It is unknown if pathogenic lamin A variants 
impinge on the ability to bind to ERK1/2. We therefore investigated the effects of the 
cardiomyopathy-associated H222P lamin A variant and a disease control variant on binding to 
ERK1/2.  
Gonzalez et al. previously reported co-immunoprecipitation of phospho-ERK1/2 
following pull-down of endogenous lamin A/C (15). However, our attempts using similar 
approaches with C2C12 cells stably expressing FLAG-tagged WT lamin A or variants with 
amino acid substitutions were unsuccessful. While we reliably co-immunoprecipitated ERK1/2 
with lamin A, the levels were very low and inconsistent when comparing WT and variants of 
lamin A between experiments (data not shown). We surmised that this was due to the technical 
challenge inherent in extracting and solubilizing lamin A/C, an intermediate filament protein, 
from the nuclear lamina.  
Traditionally, chaotropic agents such as high concentrations of urea or sodium dodecyl 
sulfate (SDS) have been used to extract and solubilize lamin A/C. Based on our attempts to 
immunoprecipitate both endogenous or overexpressed lamin A and its variants, we concluded 
that methods that effectively extract and solubilize the protein also destroy meaningful in vivo 
associations. To circumvent this technical hurdle, we pursued an alternative approach utilizing in 
vitro binding using immunoprecipitated lamin A (Fig. 5A). Plasmids encoding FLAG-tagged 
WT lamin A, H222P lamin A, or R482W lamin A (a variant causing Dunnigan-type familial 
partial lipodystrophy) were transiently transfected into 293T cells, which were then lysed in 
extraction buffer containing ionic detergents (0.1% SDS and 0.5% sodium deoxycholate) and 
sonicated. The overexpressed FLAG-tagged lamin A was then immunoprecipitated using M2 
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anti-FLAG affinity gel. The purified gel-lamin A complexes DFWLQJDV³EDLW´ were washed and 
incubated with whole extracts from C2C12 cells (source of ERK1/2 DFWLQJDV³SUH\´, which 
were prepared using a lysis buffer lacking ionic detergents (see Materials and Methods for 
details). The bait-prey complexes were pelleted/washed, eluted, and assessed for the presence of 
ERK1/2 using SDS-PAGE and Western blotting. Whole cell extracts from C2C12 cells treated 
with either 20% fetal bovine serum or serum starved for 30 minutes were used to ascertain 
whether the phosphorylation status of ERK1/2 influenced its biding to lamin A. We also repeated 
the experiment using extracts from immortalized mouse embryonic fibroblasts lacking lamin 
A/C (iMEF-/-) to remove potential confounding influence of the presence of endogenous wild 
type lamin A/C in C2C12 cell extracts. Increased and reduced phospho-ERK1/2 levels following 
high serum treatment and serum starvation, respectively, were confirmed in aliquots of C2C12 
and iMEF-/- extracts used as prey (Fig. S4A).  We observed that, relative to WT and R482W 
lamin A, H222P lamin A co-precipitated with the greatest amount of total ERK1/2 from both 
C2C12 and iMEF-/- extracts (Fig. 5B and Fig. S4B). We observed no difference in lamin A 
binding to ERK1/2 between 20% serum-treated and serum starved C2C12 and iMEF-/- extracts 
used as prey (Fig. 5B and S4B), suggesting that the phosphorylation status of ERK1/2 did not 
affect their binding to lamin A.  
 To ascertain the level of phospho-ERK1/2 from the total ERK1/2 that co-precipitated 
with lamin A, we performed western blot with anti-phospho-ERK1/2 antibodies. However, 
despite multiple attempts with several commercially available phospho-ERK1/2 antibodies, we 
were not able to detect phospho-ERK1/2. As an alternative strategy, we performed confocal 
microscopy on C2C12 cells stably expressing either FLAG-tagged WT or H222P lamin A. We 
previously showed that these cells expressed identical levels of the FLAG-tagged lamin A 
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transgenes (23). We labeled fixed cells with phospho-ERK1/2 antibodies to assess its 
localization. Confocal micrographs showed that phospho-ERK1/2 were localized to the nuclear 
rim in cells expressing H222P lamin A to a greater degree than in those expressing the WT 
protein (Fig. 5C). Linear fluorescence intensity measurements across the nucleus along the 
length of the cell as well as Pearson's r analysis confirmed our initial observation of greater co-
localization between phospho-ERK1/2 and H222P lamin A compared to WT lamin A (Fig. 5D). 
Similar results were obtained in C2C12 cells stably expressing non-FLAG-tagged WT lamin A, 
N195K (another point mutant variant associated with striated muscle disease) lamin A and 
H222P lamin A variants (Fig. S5), indicating that the FLAG tag did not alter lamin A-ERK1/2 
binding characteristics. These results demonstrate that the H222P amino acid substitution in 
lamin A results in increased binding to total ERK1/2, relative to the WT or lipodystrophy-
associated R482W variant, and, as a consequence, enhanced sequestration of phospho-ERK1/2 at 
the nuclear lamina. 
 
Deletion of Dusp4 in LmnaH222P/H222P mice has beneficial effects on cardiac function and 
prolongs survival. To test directly the hypothesis that Dusp4 expression is a key contributor to 
the pathophysiology of cardiomyopathy, we crossbred LmnaH222P/H222P mice to Dusp4-/- mice 
(Fig. 6A). We confirmed the lack of DUSP4 protein expression in ventricular tissue extracts 
from the resulting interbred mice (Fig. S6). Depleting DUSP4 from male LmnaH222P/H222P mice 
(LmnaH222P/H222P/Dusp4-/-) significantly increased their medial survival (Fig. 6B). 
Echocardiography showed that prolonged survival correlated with improved cardiac parameters 
such as reduction in left ventricular end systolic diameter as well as increases in fractional 
shortening and ejection fraction (Fig. 6C, D). We also observed a subtle but significant decrease 
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in fractional shortening in Lmna+/+/Dusp4-/- mice relative to Lmna+/+/Dusp4+/+ controls, which 
has been reported previously (44). 
 We examined hematoxylin and eosin stained sections of left ventricles from 20 week-old 
Lmna+/+/Dusp4-/- (control), LmnaH222P/H222P/Dusp4+/+, and LmnaH222P/H222P/Dusp4-/- mice (Fig. 
7A). Consistent with our recent report (22), we observed pronounced cytoplasmic vacuolation 
within cardiomyocytes of the papillary muscles accompanied by variations in myocyte size in 
hearts of LmnaH222P/H222P/Dusp4+/+ mice (Fig. 7A).  These abnormalities were virtually absent in 
papillary muscles of Lmna+/+/Dusp4-/- mice (Fig. 7A, left panel) and significantly reduced 
(approximately 2-fold reduction) in LmnaH222P/H222P/Dusp4-/- mice (Fig. 7A, right panel and Fig. 
7B). 0DVVVRQ¶VWULFKURPHVWDLQLQJWRGHWHFWILEURVLVUHYHDOHGQRVLJQLILFDQWGLfferences between 
the genotypes (data not shown). 
 We previously showed that autophagic responses were blunted in hearts of mice 
overexpressing Dusp4 due to aberrant activation of the AKT-mTORC1 pathway (23, 24). 
Therefore, we assessed AKT-mTORC1 signaling by assessing the activation (phosphorylation) 
of AKT and mTOR (a central component of mTORC1) as well as markers of autophagy in 
LmnaH222P/H222P/Dusp4-/- mice. Western blot analyses of protein extracts isolated from ventricular 
tissue of LmnaH222P/H222P/Dusp4+/+ and LmnaH222P/H222P/Dusp4-/- mice revealed significantly 
reduced AKT phosphorylation with the deletion of Dusp4; however, the reduction in mTOR 
phosphorylation did not attain statistical significance (Fig. 7C). To assess the impact of 
incomplete deactivation of mTOR on autophagy, we measured autophagic responses by 
detecting for increased levels of lipidated microtubule-associated protein-1 light chain 3 E 
(LC3B-II) from its non-lipidated form (LC3B-I) as an indirect measure of autophagosome 
formation (45, 46) (Fig. 7C). We also measured the level of p62/SQSTM1 (p62), a LC3B-
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binding protein that is degraded following autophagosome fusion with lysosomes as an indirect 
measure of autophagic flux (Fig. 7C). Consistent with incomplete deactivation of mTOR, our 
results showed a trend towards autophagy activation but the change in levels of LC3B-II and p62 
in hearts of LmnaH222P/H222P/Dusp4-/- mice did not reach statistical significance (Fig. 7C). These 
results indicate that AKT and mTORC1 signaling may be decoupled in hearts of 
LmnaH222P/H222P/DUSP4-/- mice. We did observe a statistically significant enhancement in 
phospho-ERK1/2 level, most likely due to the depletion of DUSP4 (Fig. 7C). 
 
Discussion 
Our results show that Dusp4 contributes to the pathogenesis of LMNA cardiomyopathy. The 
delayed kinetics of cardiac Dusp4 expression in female LmnaH222P/H222P mice relative to male 
counterparts coincided with the corresponding delay in the onset detectable heart dysfunction 
(19). A previous study found that androgen receptor accumulation in the nucleus of 
cardiomyocytes contributes to the sex-dependent differences observed in the LmnaH222P/H222P 
mice (47). This suggests a putative crosstalk mechanism between ERK1/2-Dusp4 and androgen 
receptor function. In support of this idea, a previous report demonstrated that testosterone 
induces cardiomyocyte hypertrophy through ERK1/2-dependent mTORC1 activation (48). Sex-
dependent differences have also been reported in patients with LMNA cardiomyopathy. Men with 
the disease are more likely to succumb to malignant ventricular arrhythmia and end-stage heart 
failure (49, 50). However, no differences are observed in the age of onset or the rate of disease 
progression to end-stage heart failure or death (49). It is unclear whether the sex differences in 
patients with LMNA cardiomyopathy are mediated by LMNA-specific mechanisms or due to 
better overall prognosis in women with heart failure (51, 52). 
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 We showed that the enhanced ERK1/2 signaling is predominantly responsible for the 
increased Dusp4 expression in response to the H222P Lmna mutation. This is in contrast to other 
instances in which direct perturbations of genetic loci involving epigenetic mechanisms occur as 
a direct consequence of Lmna mutations (13, 14, 42). The increased Ac-H3 at the Dusp4 locus 
was dependent on ERK1/2 signaling in C2C12 cell culture models expressing WT and H222P 
lamin A variants indicating that transcription promoting epigenetic changes occurs as a 
consequence of kinase activation. In addition, Dusp4 expression was significantly reduced in 
hearts of LmnaH222P/H222P mice lacking ERK1 at both 4 and 16 weeks of age, further confirming 
that ERK1/2 signaling underlies Dusp4 expression. 
 In addition to cardiomyopathy, LmnaH222P/H222P mice develop muscular dystrophy (19). 
We previously showed that quadriceps of 16 week-old male LmnaH222P/H222P mice also exhibit 
enhanced Dusp4 expression albeit to a lesser degree relative to the heart (23). The current study 
demonstrates similar findings in quadriceps of female LmnaH222P/H222P mice. Elevated phospho-
ERK1/2 levels have been observed in multiple skeletal muscle groups of LmnaH222P/H222P mice 
and systemic administration of small molecule inhibitors of MEK1/2 improves skeletal muscle 
pathology and limb grip strength (53). These studies collectively suggest that activation of 
ERK1/2 in skeletal muscle may be responsible for the enhanced Dusp4 expression and underlie 
skeletal muscle pathogenesis. 
 Our results from in vitro models showed increased total ERK1/2 binding to the 
myopathy-associated lamin A H222P variant relative to the WT protein or the lipodystrophy-
causing R482W variant. This enhanced binding did not appear to be influenced by ERK1/2 
phosphorylation status, which is consistent with previously published observations (16). We also 
showed a corresponding increase in phospho-ERK1/2 localization at the nuclear lamina in 
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H222P lamin A-expressing C2C12 cells. These results are consistent with the hypothesis that the 
H222P amino acid substitution in lamin A/C causes enhanced total ERK1/2 binding irrespective 
of phosphorylation status and, as a consequence, increased localization of phosphorylated 
ERK1/2 at the nuclear lamina. Despite our data from in vitro binding and cell culture models, we 
acknowledge that the significance of the apparently enhanced binding affinity of the H222P 
lamin A variant to ERK1/2 remains uncertain in driving kinase hyper-activation in LMNA 
cardiomyopathy. First, it is difficult to explain how this altered binding affinity observed in the 
cultured cells we examined could lead to the observed selectivity of ERK1/2 hyperactivation in 
striated muscle in animals (17, 23). Secondly, loss of lamin A/C in mice and haploinsufficiency 
in humans leads to cardiomyopathy (2, 54). This would not lead to enhanced ERK1/2 binding to 
lamin A/C but could hypothetically alter the properties of the entire lamina, including B-type 
lamins, with regards to kinase sequestration.  
 Our data demonstrating ERK1/2 signaling as the predominant driver of Dusp4 expression 
coupled with its established function as a negative feedback inhibitor of ERK1/2 present an 
obvious conundrum: how are levels of both phosphorylated ERK1/2 and Dusp4 enhanced in the 
hearts of LmnaH222P/H222P mice? Furthermore, the original study linking ERK1/2 activation and 
LMNA cardiomyopathy demonstrated increased nuclear localization of phospho-ERK1/2 in 
hearts of LmnaH222P/H222P mice (17), which further contributes to the apparent paradox. A 
hypothesis consistent with our observations is one in which the scaffolding function of the 
nuclear lamina is disrupted in a way that disrupts efficient binding between ERK1/2 and Dusp4, 
in a manner similar to the role of lamin A/C bridging the interaction between activated ERK1/2 
and c-Fos (15, 55). Moreover, it was recently shown that activated ERK1/2 catalyzes a 
phosphorylation reaction on the C-terminus of DUSP4 protein that increases its half-life (56, 57). 
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Therefore, the potential scaffolding role of the nuclear lamina facilitating the interaction of 
DUSP4 with ERK1/2 may be a critical regulatory point for ERK1/2 signal output. The disruption 
of this function by the expression of the H222P lamin A/C variant may facilitate the continued 
activation of ERK1/2 downstream effectors (one of which is DUSP4), while the newly expressed 
DUSP4 is unable to efficiently dephosphorylate ERK1/2. This hypothesis remains to be tested. 
 Arguably, the most significant finding of our current study is the salutary effects of 
Dusp4 gene deletion in the LmnaH222P/H222P background. LmnaH222P/H222P/Dusp4-/- mice displayed 
improved cardiac performance parameters, mainly due to the preservation of systolic 
dimensions, and this improvement was correlated with prolonged survival compared to 
LmnaH222P/H222P/Dusp4+/+ mice. Although male LmnaH222P/H222P/Dusp4+/+ mice develop significant 
cardiac fibrosis at 6 months of age (19), we observed minimal fibrosis in both 
LmnaH222P/H222P/Dusp4+/+ and LmnaH222P/H222P/Dusp4-/- male mice at around 4.5 months of age, 
probably due to the earlier age at which the analysis was performed. We did observe abnormal 
myofibers, particularly in the papillary muscles in the LmnaH222P/H222P/Dusp4+/+ mice in the form 
of cytoplasmic vacoulation, and these abnormalities were significantly reduced in the 
LmnaH222P/H222P/Dusp4-/- mice. These improvements were observed despite higher levels of 
phospho-ERK1/2 in hearts of LmnaH222P/H222P/Dusp4-/- mice relative to LmnaH222P/H222P/Dusp4+/+ 
mice. We surmise the increased phospho-ERK1/2, despite the lack of DUSP4 expression, may 
undercut the salutary effects of Dusp4 deletion. By extension, we hypothesize that activated 
ERK1/2 and overexpression of DUSP4 separately contribute to LMNA cardiomyopathy. 
Furthermore, the concurrent ERK1/2 activation and DUSP4 overexpression, which is the cardiac 
expression profile in the LmnaH222P/H222P/Dusp4+/+ mice, may be required for the full penetrance 
of the disease phenotype. We previously showed that transgenic mice overexpressing Dusp4 
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specifically in cardiomyocytes displayed decreased phospho-ERK1/2 and increased DUSP4 
expression in the heart and developed a subtler cardiac phenotype in the form of reduced systolic 
dimension compared to LmnaH222P/H222P mice (23). In this study, we present evidence of a subtle 
but significant reduction in left ventricular fractional shortening in hearts of 20 week-old 
Lmna+/+/Dusp4-/- mice relative to Lmna+/+/Dusp4+/+ mice. Phospho-ERK1/2 levels were variable 
with only some samples showing slight increases (data not shown). This is consistent with a 
previous report studying Lmna+/+/Dusp4-/- mice, although in the decreases in fractional 
shortening were observed later at 8 months of age (44). Additionally, LmnaH222P/H222P/Dusp4-/- 
mice showed improved cardiac performance parameters relative to LmnaH222P/H222P/Dusp4+/+ 
mice, mainly due to the preservation of systolic dimensions, despite modestly increased 
phospho-ERK1/2 levels. These data collectively suggest that activated ERK1/2 and DUSP4 
uniquely contribute to the pathogenesis of LMNA cardiomyopathy and that both could be 
targeted for effective therapy.  
 AKT-mTORC1 signaling is aberrantly activated in the hearts of LmnaH222P/H222P and mice 
lacking lamin A/C and its activation prevents cardiac induction of autophagy, which is thought to 
underlie the pathogenesis of cardiomyopathy (24, 58). We also previously showed that enhanced 
cardiac expression of Dusp4 causes aberrant AKT-mTORC1 activation (23). Although the levels 
of activated AKT (phosphorylation of S473) were significantly reduced in hearts of 
LmnaH222P/H222P/Dusp4-/- mice relative to LmnaH222P/H222P/Dusp4+/+ mice, a corresponding 
reduction in mTOR activation and subsequent activation of autophagy were not statistically 
significant. These results suggest a decoupling between AKT and mTOR activation in the hearts 
of LmnaH222P/H222P/Dusp4-/- mice. AKT activates mTORC1 through an intermediary termed 
tuberin sclerosis complex (TSC) composed of TSC1, TSC2, and Rheb (59). TSC2 is a GTPase 
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activating protein targeting Rheb, a Ras family GTPase (59). Activated AKT catalyzes an 
inhibitory phosphorylation on multiple serine and threonine residues on TSC2, which reduces the 
Rheb GTPase activity, and increases the level of GTP-bound Rheb (60, 61). The GTP-bound 
Rheb then directly binds and activates mTOR (62), leading to downstream effector functions of 
mTORC1 such as inhibition of autophagy (63). Notably, activated ERK1/2 can also catalyze an 
inhibitory phosphorylation on TSC2 at the unique serine 664 residue that results in mTOR 
activation (64). Given that DUSP4 is a feedback inhibitor of ERK1/2 signaling, the depletion of 
DUSP4 and the resulting increase in the level of activated ERK1/2 in the hearts of 
LmnaH222P/H222P/Dusp4-/- mice may lead to an incomplete deactivation of mTOR despite AKT 
inactivation. Our results indicate that although the genetic deletion of Dusp4 leads to improved 
survival and cardiac function, its full beneficial effect may be blunted by the incomplete 
deactivation of mTOR (and hence partial activation of autophagy) mediated by another process, 
such as enhancement of the ERK1/2-TSC2 pathway. Alternatively, it is plausible that AKT-
dependent pathways may contribute more substantially to the deterioration of cardiac function 
and mortality than mTOR-mediated mechanisms in the development of LMNA cardiomyopathy. 
Although the AKT pathway is necessary for the beneficial effects of exercise-induced 
physiological hypertrophy (65), prolonged activation leads to cardiomyopathy whereas transient 
activation improves cardiac function (66, 67). 
 From a therapeutic perspective, the development of pharmacological inhibitors targeting 
DUSP4 has trailed behind functional and structural discoveries. Part of the reason is due to the 
nature of DUSP4 structure as well as its biochemical functionality. The active sites of DUSPs are 
~6 Å, which is shallower than those of protein tyrosine phosphatases at ~9 Å (68).  The active 
site of DUSP4 is even shallower than other DUSPs (69), presenting a significant challenge in 
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achieving specificity in inhibition with small molecules. Furthermore, DUSP4-mediated 
dephosphorylation is a first-order reaction requiring only direct binding to its target (68). 
Because ATP hydrolysis is dispensable for phosphatase-mediated dephosphorylation, DUSP4 
lacks an ATP binding pocket commonly targeted by small molecule inhibitors, presenting an 
additional obstacle in the development of effective and specific drug development. An 
alternative strategy to inhibit DUSP4, as supported by our results, is to target ERK1/2 signaling. 
As stated above, activated ERK1/2 not only stimulate Dusp4 transcription but also stabilize the 
protein by phosphorylating its C-terminus, leading to an increased half-life (56, 57). Given our 
conclusion that ERK1/2 are dominant drivers of Dusp4 expression in LMNA cardiomyopathy, as 
well as accumulating evidence showing that their blockade has therapeutic benefit in mouse 
models of LMNA cardiomyopathy (18, 20-22, 70), a treatment strategy targeting ERK1/2 
(perhaps in combination with AKT inhibition) presents a superior therapeutic option than direct 
DUSP4 inhibition. 
 
Materials and Methods 
 Mice - The Columbia University Medical Center Institutional Animal Care and Use 
Committee approved all protocols using animals and the investigators adhered to the NIH Guide 
for the Care and Use of Laboratory Animals. LmnaH222P/H222P mice (C57BL/6 genetic 
background) were obtained from Dr Gisèle Bonne (Institut de Myologie, Paris) and genotyped 
using tail biopsies as described (19). Dusp4-/- mice (C57BL/6 genetic background) genotyped as 
described (71). Heart tissue from intercrosses between LmnaH222P/H222P and Mapk3-/- mice (from 
Drs. Gilles Pagès and Jacques Pouysségur - Université de Nice) were generated in mixed 
background (129 and C57BL/6) and genotyped as described (21, 72). Genotyping was performed 
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by PCR using genomic DNA isolated from tail clippings. Mice were fed a chow diet and housed 
in a disease-free barrier facility with 12/12 hr light/dark cycles.  
Cells - Generation and characterization of C2C12 myoblasts stably expressing FLAG-
tagged WT, H222P, and R482W lamin A as well as the non-FLAG-tagged versions of WT, 
N195K, and H222P lamin A have been described elsewhere (23). For FLAG-lamin A expressing 
cells, cDNAs from these cells were PCR amplified with primers corresponding to FLAG and 
mouse lamin A and the resultant amplicons were sequenced to confirm the correct WT and 
H222P lamin A variant expression. These cells as well as 293T cells, iMEF-/- (from Lmnaǻ-11 
mice (73), previously Lmna-/- mice (54)) and unmodified C2C12 cells were cultured in 
Dulbecco's modified Eagle's medium containing 10% fetal bovine serum (FBS). All C2C12 cells 
were subcultured prior to reaching approximately 80% cell confluency. 
 RNA isolation and qPCR - Total RNA was isolated using TRIzol and cDNAs generated 
from 1 Pg primed with a 1:1 ratio of random hexameric primers and oligo dT using SuperScript 
Reverse Transcriptase II (Invitrogen). qPCR was performed on an ABI 7300 Real-Time PCR 
system (Applied Biosystems) using SYBR green (USB). qPCR primers for Dusp1-11, Nppa, 
Nppb, Col1a2, and Hprt have been described elsewhere (17, 20, 70, 74). Col4a1 (For - ¶-
ATGGCATTGTGGAGTGTCAA; Rev - ¶-TGTCCAGGGAAACCAATCTC), Col4a2 (For - 
¶-CATCCGTCGGAGATGAAGAT; Rev - ¶-CCTTTGTACCGTTGCATCCT), and E2f1 (For 
- ¶-AGGGTCCCTATGGAAGAGGA; Rev - ¶-CAGGTCCCCAAAGTCACAGT) primers 
were generated using Primer3 (http://bioinfo.ut.ee/primer3-0.4.0/primer3/). Hprt mRNA was 
assessed to ensure equal fidelity in enzymatic reactions and was used as internal control to 
normalize qPCR results. Fold-changes in gene expression were determined by the ''Ct method 
(75) and are presented as fold-change over WT controls. 
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 Protein extraction and western blot analysis - Hearts were excised from sacrificed mice 
and tissue homogenized in radioimmunoprecipitation assay (RIPA) buffer (Sigma-Aldrich) with 
protease inhibitor cocktail (Roche), 1 mM phenylmethylsulfonyl fluoride (Sigma-Aldrich), and 1 
mM sodium vanadate. Following brief sonication (Dismembrator Model F60, Thermo Fisher 
Scientific), 15 to 30 Pg of protein extract was loaded for SDS-PAGE. Antibodies against the 
following proteins were purchased from Cell Signaling Technology: phospho-AKT (Ser473 
#4060), AKT (#4691), phospho-ERK1/2 (#9101), LC3B, (#2775), phospho-mTOR (Ser2448 
#2971), mTOR (#2972), phospho-Smad3 (#9520), Smad2/3 (#3102), phospho-p53 (Ser15 
#9284), and p53 (#2524). Antibodies against the following proteins were purchased from Santa 
Cruz Biotechnology: ERK1/2 (sc-94), DUSP4 (sc-1200), ANP (sc-20158), and D-tubulin (sc-
12462-R). GAPDH antibodies were purchased from Ambion (#AM4300). Quantification of blots 
was performed with ImageJ (76), normalized to loading controls as indicated, and presented as 
arbitrary units or fold change over untreated or WT controls. 
 Epigenetic analysis - In silico methylation analysis of murine Dusp4 upstream promoter 
sequence of C57BL/6J reference sequence (NCBI - NC_000074.6) was performed using 
EMBOSS Cpgplot (http://www.ebi.ac.uk/Tools/seqstats/emboss_cpgplot/). For methylation 
analysis using restriction enzymes, purified genomic DNA from hearts of Lmna+/+ and 
LmnaH222P/H222P mice was digested overnight with restriction enzyme SphI (New England 
BioLabs), which cuts at sites -7067 and +6474 from the Dusp4 start codon, generating an 
approximately 13.5 kbp contiguous genomic sequence spanning the Dusp4 predicted TSS (37). 
The digested DNA was aliquoted and subsequently cleaved by restriction enzyme digestion with 
ZraI, BsrBI, Ahdl, or BlpI (New England BioLabs) followed by enzymatic reaction cleanup. 
Then, 50 ng of cleaved genomic DNA was amplified by PCR using the following primers: For 
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¶-*$$*$&&7&&$&$&**$*$*DQG5HY¶-TTGCTAGCTAGGGCTGCTTC for ZraI site 
(-568 bp from start codonDQG)RU¶- CAGCTAGCTCCCCAGC77$&DQG5HY¶- 
GGCACCCACGTTTACCTTTA for BsrBI site (+134 bp). Hprt (same primers used for RT-
qPCR analysis) was assessed as the internal loading control. ChIP assay was performed using 
EZ-&K,30LOOLSRUHDFFRUGLQJWRWKHPDQXIDFWXUHU¶VLQVWUXFWLRQVIRUC2C12 cells stably 
expressing FLAG-tagged WT and H222P lamin A. Glucose starvation and 20 PM PD98059 
treatment of these cells were performed as described previously (23). Minor modifications were 
made for the heart tissue ChIP as established by Weinmann and Farnham (77). Briefly, 
approximately 80 mg of ventricular tissue was minced into small pieces (between 1-3 mm3) and 
crosslinked with 1% formaldehyde in 800 Pl of PBS (1 ml PBS per 100 mg of tissue) with 
protease inhibitor cocktail II (PI-II, provided by EZ-ChIP) for 15 minutes. Crosslinking was 
quenched by adding freshly prepared glycine to a final concentration of 0.12 5M and incubating 
at room temperature for 5 minutes. The crosslinked tissue pieces were pelleted, washed twice 
with ice cold PBS with PI-II, and homogenized in 1 ml of SDS lysis buffer + PI-II as indicated 
and provided by the manufacturer. Chromatin shearing (750 -250 bp fragments) was achieved 
using a sonicator (Dismembrator Model F60) for a total of 4 minutes at 20 second intervals for 
C2C12 cells and 7 minutes for the heart tissue. Antibodies against Ac-H3 and isotype-matched 
control antibodies (both provided by the manufacturer) were used to immunoprecipitate Ac-H3 
bound DNA and non-specific DNA, respectively. In addition, 1% of total sheared chromatin was 
FROOHFWHGDQGDVVHVVHGDV³LQSXW´WRHQVXUH comparable levels of starting material. The purified 
DNA isolated from immunoprecipitated and input samples were subjected to qPCR using 
SULPHUV)RU¶- &&&&&7&7***77*7$$$*7DQG5HY¶- GCTCGGGGACTTTGTGAAT 
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for primer set 1 and )RU¶- CAGCTAGCTCCCCAGCTTAC DQG5HY¶- 
GGCACCCACGTTTACCTTTA for primer set 2. 
 Microscopy and histopathological analysis - Immunofluorescence staining was 
performed on stable methanol:acetone (3:1)-fixed C2C12 cells using standard protocols with 
anti-phospho-ERK1/2 (Cell Signaling Technology, #9101), anti-FLAG (for FLAG-tagged lamin 
A - clone M5, Sigma-Aldrich), and lamin A/C (for non-FLAG mutant variants - MANLAC1) 
antibodies. Confocal images were captured using a LSM 510 confocal laser scanning system 
(Carl Zeiss) in the Confocal and Specialized Microscopy Core at the Herbert Irving 
Comprehensive Cancer Center (Columbia University Medical Center). Fluorescence intensity 
profiles of lamin A (and its variant used in the study) and phospho-ERK1/2 were determined 
using the ImageJ software (76) using methods similar to those described by Gonzalez et al (15). 
Linear fluorescence intensity of lamin A and phospho-ERK1/2 were measured from 30 
individual cells from two separate experiments. Co-localization analyses of lamin A and 
phospho-(5.VLJQDOVDQGWKHFDOFXODWLRQRI3HDUVRQ¶Vr were performed using JACoP ImageJ 
plugin (78). Hemotoxylin and eosin staining of formaldehyde-fixed and paraffin-embedded heart 
was performed by Molecular Pathology Shared Resource in the Herbert Irving Comprehensive 
Cancer Center (Columbia University Medical Center). Stained slides were scanned with a Leica 
SCN400 auto brightfield whole slide digital scanning system and visualized using the Aperio 
ImageScope software (Leica Systems). The quantification of papillary muscle cytoplasmic 
vacuolation was performed at 20X magnification on 40 contiguous 100 Pm2 images (a total area 
of 800 Pm x 500 Pm) per papillary muscle in a blinded fashion by an investigator blind to mouse 
genotype. The data are presented as number of vacuoles in the papillary muscle within the 800 
Pm x 500 Pm field analyzed. 
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 Lamin A variant immunoprecipitation and in vitro binding analysis - 293T cells were 
transiently transfected with expression vectors (pEGFP-C1, Invitrogen) containing cDNA 
sequences for either the WT, H222P, or R482W lamin A, in which the EGFP sequence was 
replaced by the FLAG sequence in the backbone vector. The vectors were confirmed by DNA 
sequencing. The transfected cells were lysed in RIPA buffer (Sigma-Aldrich) with PI and the 
FLAG-tagged lamin A and its point mutant variants were solubilized by sonication 
(Dismembrator Model F60) and immunoprecipitated using anti-FLAG M2 affinity agarose gel 
(Sigma-Aldrich). The precipitated agarose gel was washed twice with 1X RIPA buffer followed 
by another two washes with 0.5X RIPA buffer and stored for future use. C2C12 and iMEF-/- that 
were either serum starved or stimulated with 20% FBS were lysed in 1X Cell Lysis Buffer (Cell 
Signaling Technology), which lacks ionic detergents. The isolated cell extracts were added to the 
immunoprecipitated lamin A in equal volumes and the mixture was incubated overnight at 4ºC 
rotating end-over-end. The protein complexes were washed twice in 0.5X Cell Lysis Buffer 
followed by two washes with 1X Cell Lysis Buffer. The protein complexes were eluted from the 
agarose gel by boiling in 2X Laemmli (79) buffer containing 5% E-mercaptoethanol and 
resolved by SDS-PAGE. 
 Transthoracic echocardiography and survival analysis - Lmna+/+/Dusp4+/+, 
Lmna+/+/Dusp4-/-, LmnaH222P/H222P/Dusp4+/+, and LmnaH222P/H222P/Dusp4-/- mice were anesthetized 
with 1-2% isoflurane and placed on a heating pad (37°C) attached to an electrocardiographic 
monitor. Echocardiography was performed using Vevo 770 imaging system (VisualSonics) 
equipped with a 30-MHz transducer. Parameters were measured for at least three cardiac cycles. 
An echocardiographer blind to mouse genotype performed the examinations and interpreted the 
results. Survival analysis was performed until time of death or signs of significant distress 
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requiring euthanasia. Specific signs of significant distress included 1) difficulty with normal 
ambulatory movement, 2) failure to eat or drink, 3) significant weight loss of more than 20%, 4) 
depression, 5) unkempt hair coat, and 6) significant respiratory distress. A staff veterinarian at 
the Institute of Comparative Medicine at Columbia University Medical Center, blind to mouse 
genotype, determined if euthanasia was required. Those requiring euthanasia were sacrificed 
according to the protocol of the Institute of Comparative Medicine consistent with American 
Veterinary Medical Association guidelines.  
 Statistical analysis - Graphpad (Prism Software) was used to perform statistical analyses. 
Statistical significance of binary variables from scanned western blots, qPCR results, and 
papillary muscle vacuole quantification were determined by a 2-WDLOHGXQSDLUHG6WXGHQW¶Vt-test 
with a value of P < 0.05 considered significant. Values with error bars shown in figures are 
means ± standard errors of means. Sample sizes are indicated in the figure legends. 
Echocardiographic measurements comparing the four different genotypes were determined by 
one-way ANOVA with post-KRF7XNH\¶VPXOWLSOHFRPSDULVRQWHVWP < 0.05 considered 
significant). Mouse survival was analyzed using the Kaplan-Meier estimator and the differences 
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Figure Legends 
Figure 1. DUSP4 expression is enhanced in the ventricular tissue of female LmnaH222P/H222P 
mice. A) qPCR analysis of Dusp1-Dusp11 mRNA in hearts of 20 week-old female 
LmnaH222P/H222P mice compared to Lmna+/+ (WT) mice. Values are means ± standard errors; n = 3 
for each genotype. B) qPCR analysis of Dusp4 mRNA in hearts of 10, 20, and 30 week-old 
female LmnaH222P/H222P and Lmna+/+ mice; n = 3. C) qPCR analysis of Dusp4 mRNA in indicated 
tissues from 30 week-old female Lmna+/+ and LmnaH222P/H222P PLFH³6.0´GHQRWHVVNHOHWDO
muscle (quadriceps); n = 3. D) Western blot analyses (left panel) of DUSP4, phospho-ERK1/2 
(pERK1/2), total ERK1/2 (ERK1/2), phospho-serine 473 AKT (pAKT), and total AKT (AKT) in 
hearts of 10 to 30 week-old female Lmna+/+ and LmnaH222P/H222P (LmnaH222P) mice. Values are 
means ± standard errors; n = 3. Numbers on top of blots denote individual heart samples. Right 
panel shows quantification of pERK1/2, DUSP4, and pAKT in hearts of female LmnaH222P/H222P 
mice normalized to total ERK1/2 and AKT, respectively, and presented as fold-change over WT. 
Values are means ± standard errors; n = 3. Single (*p < 0.05) and double asterisks (**p < 0.01) 
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represent p values of normalized pERK1/2, DUSP4, and pAKT quantification relative to WT 
controls at 20 and 30 weeks of age, respectively. 
 
Figure 2. Expression of markers of left ventricular dilatation and ERK1/2 and AKT signal 
activation coincide with Dusp4 expression in hearts of female LmnaH222P/H222P mice. A) 
qPCR analysis of Nppa and Nppb mRNA in hearts of 10, 20, and 30 week-old female Lmna+/+ 
(WT) and LmnaH222P/H222P mice; n = 3. B) Western blot analyses (top panel) of atrial natriuretic 
peptide (ANP) and D-tubulin in hearts of 30 week-old female Lmna+/+ and LmnaH222P/H222P 
(LmnaH222P) mice. Numbers on top of blots denote individual heart samples. Bottom panel shows 
quantification of ANP normalized to D-tubulin. Values are means ± standard errors; n = 3. C) 
qPCR analysis of various collagen isoform mRNA in hearts of 10, 20, and 30 week-old female 
Lmna+/+ and LmnaH222P/H222P mice. Values are means ± standard errors; n = 3. 
 
Figure 3. Histone 3-acetylation in the Dusp4 promoter is enhanced in hearts of 
LmnaH222P/H222P mice and correlates with ERK1/2 signaling. A) Schematic of the Dusp4 locus 
and the locations of primer sets (black and grey arrows) used to amplify genomic DNA. ³766´
DQG³´GHQRWHSUHGLFWHGWUDQVFULSWLRQVWDUWVLWHDQGthe start codon, respectively. B) ChIP 
analyses assessing enrichment of Ac-H3 in the Dusp4 promoter of ventricular tissue isolated 
from 8 week-old male Lmna+/+ and LmnaH222P/H222P (LmnaH222P) mice; n = 3 for both primer sets 
1 and 2. C) ChIP analyses assessing enrichment of Ac-H3 in the Dusp4 promoter of C2C12 
myoblasts stably expressing WT (C2-WT) or H222P lamin A (C2-H222P) subjected to glucose 
starvation; n = 3. D) ChIP analyses assessing enrichment of Ac-H3 in the Dusp4 promoter of C2-
WT or C2-H222P subjected to glucose starvation after 1 hr pretreatment with PD98058; n = 3. 
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All values presented in this figure are means ± standard errors relative to WT, which was 
normalized to 1. The p-values are provided for pairwise comparisons that were statistically 
significant (p < 0.05). 
 
Figure 4. Genetic deletion of ERK1 impairs Dusp4 expression. A) Breeding strategy to delete 
Mapk3 (ERK1) in LmnaH222P/H222P mice. B) Western blot analyses (top panel) of phospho-
ERK1/2 and total ERK1/2 in hearts of 20 week-old male LmnaH222P/H222P/Mapk3+/+ (LmnaH222P) 
and LmnaH222P/H222P/Mapk3-/- mice. Numbers on top of blots denote individual heart samples. 
Bottom panel shows qPCR analysis of Dusp4 mRNA in hearts of 4 and 16 week-old male 
Lmna+/+/Mapk3+/+ (WT), LmnaH222P/H222P/Mapk3+/+ (LmnaH222P), and LmnaH222P/H222P/Mapk3-/- 
double knockout (LmnaH222P/Mapk3-/-) mice. Values are means ± standard errors; n = 3 for each 
sample. 
 
Figure 5. ERK1/2 preferentially binds to H222P lamin A and localizes to the nuclear 
envelope. A) Experimental design of in vitro binding analysis between immunoprecipitated 
lamin A variants and ERK1/2. WB indicates Western blot. B) Autoradiograms showing Western 
blots of immunoprecipitated WT and indicated lamin A variants incubated with whole cell 
extracts isolated from C2C12 cells subjected to either 20% fetal bovine serum or serum 
starvation. Blank indicates control samples in which blank expression vector was used to 
transfect 293T cells instead of lamin A expression vectors. Four independent experiments were 
performed with similar results. C) Confocal micrographs of C2C12 cells stably expressing either 
FLAG-tagged WT or H222P lamin A stained with FLAG and phospho-ERK1/2 antibodies. Scale 
bar = 20 Pm.  D) Fluorescence intensity profiles of WT lamin A, H222P lamin A, and phospho-
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ERK1/2 determined from line measurements along the cell length that bisect the nucleus in cells 
from panel 5C. Red shaded lines indicate WT or H222P lamin A and the green shaded phospho-
ERK1/2 measured from 30 individual cells from two separate experiments. 3HDUVRQ¶Vr (means ± 
standard errors) was calculated from a total of 6 images per experimental group across 3 
independent experiments.  
 
Figure 6. Genetic deletion of Dusp4 in LmnaH222P/H222P mice increases survival and cardiac 
performance parameters. A) Breeding strategy to delete Dusp4 in LmnaH222P/H222P mice. B) 
Kaplan-Meier estimator plot of survival of Lmna+/+/Dusp4+/+ (Lmna+/+), Lmna+/+/Dusp4-/- 
(Dusp4-/-), LmnaH222P/H222P/Dusp4+/+ (LmnaH222P/H222P), and LmnaH222P/H222P/Dusp4-/- 
(LmnaH222P/Dusp4-/-) mice. The p value was derived using log-rank (Mantel-Cox) test. C) 
Graphic representation of M-mode echocardiographic tracing measurements for left ventricular 
end systolic diameter (LVESD), left ventricular end diastolic diameter (LVEDD), fractional 
shortening (FS) and ejection fraction (EF) of hearts from Lmna+/+/Dusp4+/+ (Lmna+/+), 
Lmna+/+/Dusp4-/- (Dusp4-/-), LmnaH222P/H222P/Dusp4+/+ (LmnaH222P), and LmnaH222P/H222P/Dusp4-/- 
(LmnaH222P/Dusp4-/-) mice approximately 20 weeks of age. Values for individual mice are 
shown; horizontal lines indicate means and error bars are standard errors. ³´LQGLFDWHVWKDWWKH
comparisons were statistically significant (95% confidence interval) as determined by one-way 
ANOVA with post-KRF7XNH\¶VPXOWLSOHFRPSDULVRQWHVWNS denotes not significant. D) 
Numerical values for heart rate (HR) indicated as beats per minute (bpm), LVESD, LVEDD, FS 
and EF of hearts from Lmna+/+/Dusp4+/+ (Lmna+/+), Lmna+/+/Dusp4-/- (Dusp4-/-), 
LmnaH222P/H222P/Dusp4+/+ (LmnaH222P/H222P), and LmnaH222P/H222P/Dusp4-/- mice at approximately 
20 weeks of age. 
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Figure 7. Papillary muscle myofiber structural aberrations in the LmnaH222P/H222P mice are 
reduced with genetic deletion of Dusp4 with weak correlation with enhanced autophagy. A) 
Photomicrographs of hematoxylin and eosin stained left ventricle sections from Lmna+/+/Dusp4-/-
, LmnaH222P/H222P/Dusp4+/+, and LmnaH222P/H222P/Dusp4-/- mice. The colored boxes in the top 
panels are shown at higher magnification in the lower panels. Scale bar = 50 Pm. B) 
Quantification of papillary muscle cytoplasmic vacuolation in LmnaH222P/H222P/Dusp4+/+ 
(LmnaH222P) and LmnaH222P/H222P/Dusp4-/- (LmnaH222P/Dusp4-/-) mice from a total area of 800 Pm 
x 500 Pm per papillary muscle; n = 3 for each genotype. The data is presented as number of 
vacuoles in the papillary muscle. Values are means ± standard errors. C) Western blot analyses 
(left panel) of phospho-serine 473 AKT (pAKT), total AKT (AKT), phospho-mTOR, (pmTOR), 
total mTOR (mTOR), LC3B-I (non-lipidated), LC3B-II (lipidated), p62, phospho-ERK1/2 
(pERK1/2), total ERK1/2 (ERK1/2), and D-tubulin in protein extracts from hearts of 
LmnaH222P/H222P/Dusp4+/+ (LmnaH222P) and LmnaH222P/H222P/Dusp4-/- (LmnaH222P/Dusp4-/-) mice. 
Numbers above each lane indicate an individual mouse. Right panel shows quantification 
analysis of the blots. Values are means ± standard errors; n = 5. 
 
Abbreviations 
DUSP4  Dual specificity protein phosphatase 4 
ERK1/2  Extracellular signal-regulated kinase ½ 
MAP kinase  Mitogen-activated protein kinase 
AKT   Activated protein kinase B 
mTORC1  Mammalian target of rapamycin complex 1 
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qPCR   Quantitative real-time polymerase chain reaction 
TSS   Transcriptional start site 
5-AC   5-aza-2'-deoxycytidine 
ChIP   Chromatin immunoprecipitation 
Ac-H3   Histone-3 acetylation 
WT   Wild type 
TGF-E  Transforming growth factor-E
E2F1   E2F Transcription Factor 1 
SDS   Sodium dodecyl sulfate 
iMEF   Immortalized mouse embryonic fibroblast 
LC3B   Microtubule-associated protein-1 light chain 3 E
TSC    Tuberin sclerosis complex 
FBS   Fetal bovine serum 
RIPA   Radioimmunoprecipitation assay 
ANP   Atrial natriuretic peptide 
LVESD   Left ventricular end systolic diameter 
LVEDD  Left ventricular end diastolic diameter 
FS   Fractional shortening 
EF   Ejection fraction 
HR   Heart rate 
ANOVA  Analysis of variance 
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PHGLDWHGE\DOWHUHGSURPRWHUHQKDQFHUUHJLRQ PHWK\ODWLRQ $In-silico DQDO\VLVSUHGLFWLQJ
















0HWK\ODWLRQDQDO\VLVRIDusp4 SURPRWHULQKHDUWVRILmna DQGLmna+3+3 PLFHDVLQSDQHO(
EXWXVLQJT3&5WRGHWHFWWKHSUHVHQFHRIDPSOLFRQV9DOXHVDUHPHDQV VWDQGDUGHUURUVUHODWLYHWR
XQFXWVHWWR Q 
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6XSSOHPHQWDO )LJXUH  $VVHVVPHQW RI IDFWRUV WKDW LQGXFH Dusp4 P51$ WUDQVFULSWLRQ LQ
KHDUWV RI LmnaH222P/H222P PLFH $ :HVWHUQ EORW DQDO\VLV RI SKRVSKRU\ODWHG 6PDG S6PDG
WRWDO 6PDG 6PDG SKRVSKRVHULQH  S SS DQG WRWDO S LQ KHDUWV RI  ZHHNROG
Lmna+/+ DQG LmnaH222P/H222P PLFH 1XPEHUV RQ WRS RI EORWV GHQRWH LQGLYLGXDO PRXVH KHDUW
VDPSOHV % T3&5 DQDO\VHV RI E2f1 P51$ H[SUHVVLRQ LQ KHDUWV RI  ZHHNROG Lmna+/+ DQG




























































































$129$7DEOH 66 GI 06 6LJ
%HWZHHQJURXSV    










³66´ VXPRIVTXDUHV³GI´ GHJUHHVRIIUHHGRP³06´ PHDQVTXDUHDQG³6LJ´ VLJQLILFDQFH
'863
αWXEXOLQ
6XSSOHPHQWDOILJXUH
6XSSOHPHQWDOILJXUH'XVSH[SUHVVLRQLQKHDUWVRILmna+3+3Dusp4 DQG
Lmna+3+3Dusp4 PLFH ,PPXQREORWVRI'863DQGαWXEXOLQRQZKROHFHOOH[WUDFWV
LVRODWHGIURPYHQWULFXODUWLVVXHIURPLmna+3+3Dusp4 DQGLmna+3+3Dusp4 PLFH
%ODFNDUURZLQGLFDWHV'863EDQG
